South Korea's Celltrion has recruited Medidata to provide eClinical technology as it works to develop copycat versions of the world's top-selling biological treatments.
South Korean CRO C&R Research is adopting Medidata's eClinical technology for its trials throughout Asia, striking a partnership to bolster its data analysis technology in a fast-growing market.
Infinity Pharmaceuticals has added risk-based monitoring (RBM) to the suite of eClinical tools it sources from Medidata. The expansion of the 10-year relationship gives Infinity access to RBM technology at a time when it is gearing up for a Phase III cancer trial.
WuXi NextCODE has struck another sequencing agreement. The latest deal will see the service provider sequence samples taken from 1,000 cancer patients in San Antonio, TX.
Medidata has connected its Clinical Cloud to Apple's ResearchKit. The link means researchers can feed data gathered by ResearchKit apps into Medidata's cloud platform, where the information can be integrated with other sources of clinical trial results.
Medidata has bolstered its books with two new deals. Accenture is tightening the ties between its R&D service offering and Medidata's Clinical Cloud and Rave EDC system.
Medidata has struck a deal with Garmin to offer its clients the use of vívofit activity trackers in clinical trials. The choice of vívofit gives an indication of the characteristics clinical trial sponsors may prioritize as wearables start to take off in research.
Medidata has signed a deal with Garmin to integrate the company's wearable vitals monitor into its cloud-based data tracking technology.
Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.
Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.